Page 69 - Sohini Das

Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

Dr Reddy's plans new brands in Russia, says no issue with funds in country

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.

Madurai to Agra, smaller towns witness strong growth in sales of medicines

In terms of launches, around 68% have been in acute therapy in last 12 months, data shows

India-developed 'variant-proof' Covid vaccine likely in 2-3 years: Industry

Domestically produced variant-proof jabs are part of a global project to develop vaccines for future epidemics

Adani Group enters healthcare, will set up medical and research facilities

A subsidiary called Adani Health Ventures will commence its business operations in 'due course', says conglomerate.

India likely to extend credit line to Sri Lanka for essential medicines

The quantum of the line of credit to be extended is not yet known

Lupin logs net loss of Rs 512 cr in Q4 on rising costs, impairment expense

Quarter was challenging due to 'headwinds in the US on account of price erosion', says company.

How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit

The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore

We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Rejuvenating Cipla: After global expansion, acquisitions on cards

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Sun Pharma to launch new oral lipid lowering drug under Brillo brand

Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder

PE firm Multiples picks up 9.3% stake in BDR Pharma for Rs 685 cr

Multiples is the first private equity (PE) investor in BDR Pharma

Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line

Biological E slashes Corbevax prices by 70% to Rs 250 a dose for pvt mkt

End user would now need to pay Rs 400 per jab including the administration charge to get the shot at a private vaccination centre; move aimed at benefiting children

Biological E plans to ramp up non-vaccines business in next three years

The privately held company has a turnover of about Rs 1,000 crore, of which close to 70-80 per cent come from the vaccines business now

AXA set to launch mental health insurance in Indian group policies

The first-ever standalone product in this space will provide Rs 25,000 for virtual consultations with therapists, psychologists and life coaches, and up to Rs 1 lakh for hospitalisation

USFDA rush after 2-year lull: 20-30% new products may be open to inspection

The last two years saw limited physical inspections due to travel restrictions during the pandemic

Analgesics, other common drugs used during Covid-19 clock double-digit CAGR

Pain and fever drug Paracetamol and blood-clot preventing Enoxaparin both post growth rates beyond 20%

Cipla looks to invest more in mRNA tech; holds discussions with firms

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the commercial growth engines